home / stock / dare / dare news

DARE News and Press, Dare Bioscience Inc. From 07/06/23

Stock Information
Company Name: Dare Bioscience Inc.
Stock Symbol: DARE
Market: NASDAQ
Website: darebioscience.com
Menu
DARE DARE Quote DARE Short DARE News DARE Articles DARE Message Board
Get DARE Alerts

News, Short Squeeze, Breakout and More Instantly...
DARE - Daré Bioscience Announces Upcoming Webinar to Review Additional Data from Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder

Webinar to be held Tuesday, July 11, 2023, at 4:30 p.m. EDT Webinar to include presentations by Daré management and key opinion leaders in reproductive and sexual medicine SAN DIEGO, July 06, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in wome...
DARE - Daré Bioscience Provides Update on Activities to Support Commercial Launch of XACIATO(TM) (clindamycin phosphate) vaginal gel, 2%, FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis

SAN DIEGO, July 05, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reaffirmed its commitment to the commercial launch of XACIATO [zah-she-AH-toe] (clindamycin phosphate) vaginal gel, 2% with collaborator Organon (NYSE: OGN),...

DARE - Daré Bioscience Announces Publication in Menopause: The Journal of The North American Menopause Society of Data from Phase 1/2 Open-Label Safety and Pharmacokinetics Study of DARE-HRT1 in Healthy Postmenopausal Women

Daré Plans to Advance DARE-HRT1 into Single Phase 3 Efficacy Trial for Treatment of Vasomotor Symptoms (VMS) due to Menopause DARE-HRT1 has the potential to be the first FDA-approved monthly intravaginal ring delivering both estrogen and progestogen hormone therapy SAN DIEGO,...

DARE - Daré Bioscience to Present at the Maxim Group Virtual Healthcare Conference

SAN DIEGO, June 14, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE ), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and CEO, will present at the Healthcare Virtual Conference presented by Maxim Gr...
DARE - Daré Bioscience Announces Publication of Phase 1/2 Pharmacokinetic, Safety and Pharmacodynamic Data for DARE-VVA1 - a Potential New Hormone-Free Treatment for Vulvovaginal Atrophy - in Climacteric, the Journal of the International Menopause Society

SAN DIEGO, June 09, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced the publication of results of its Phase 1/2 clinical study of DARE-VVA1, a proprietary, investigational formulation of tamoxifen for intravaginal ad...

DARE - Daré Bioscience Announces Positive Topline Data from the Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder

Sildenafil Cream-treated patients showed meaningful improvement in the co-primary endpoint assessment that evaluated change from baseline in the Arousal-Sensation Domain of the Sexual Function Questionnaire Sildenafil Cream-treated patients also showed improvements in the secondary ...

DARE - Daré Bioscience to Participate in Two Upcoming Conferences: 2023 BIO International Convention and the Longwood Healthcare Leaders Spring 2023 MIT Conference

SAN DIEGO, June 01, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE ), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and CEO, will participate in two conferences during the week of June 5 th : ...
DARE - Daré Bioscience Announces Availability of Publication on the Patient-Centered Concept Elicitation Study for Female Sexual Arousal Disorder in The Journal of Sexual Medicine

The Concept Elicitation Study Informed the Selection of the Primary, Secondary, and Exploratory Endpoints Included in the Phase 2b RESPOND Clinical Study Evaluating the Efficacy and Safety of Sildenafil Cream, 3.6% in Premenopausal Patients with Female Sexual Arousal Disorder Topline Da...

DARE - Daré Bioscience, Inc. (DARE) Q1 2023 Earnings Call Transcript

2023-05-11 22:10:22 ET Daré Bioscience, Inc. (DARE) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Sabrina Martucci Johnson – President and Chief Executive Officer John Fair – Chief Commercial Officer Lisa Walters...

DARE - Dare Bioscience GAAP EPS of -$0.09

2023-05-11 11:45:10 ET Dare Bioscience press release ( NASDAQ: DARE ): Q1 GAAP EPS of -$0.09. Cash and cash equivalents: $19.8 million at March 31, 2023. For further details see: Dare Bioscience GAAP EPS of -$0.09
Previous 10 Next 10